Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Initiates Restructuring Program To Save Up To $475M Annually

Executive Summary

The medtech giant will simplify its organizational structure, consolidate operations and give more autonomy to its individual operating units.

You may also be interested in...



Medtronic ‘Plays Offense’ Despite Pandemic Challenges, Q1 Results Provide Optimism

Medtronic’s revenue of $6.5bn in the first quarter of fiscal 2021 represents a 17% fall year-over-year, but it still beat analysts’ projections.

ADA 2020: Medtronic Explains Strategy To Return Growth To Diabetes Business

Medtronic will launch its next-generation MiniMed 780G insulin pump while continuing to develop complementary technologies to close the competitive gap with its rivals in the diabetes market.

Novocure Transforms Patient Support System During Pandemic

The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.

Topics

Related Companies

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel